COMP <GO>
ACAD vs IRON // FORWARD P/E MULTIPLE
ACADIA Pharmaceuticals Inc. (NASDAQ) VS. Disc Medicine Inc. (NASDAQ) • 15-METRIC TALLY: ACAD 6
— IRON 4
▲ FORWARD P/E MULTIPLE LEADER: ACAD
LAST: $20.47 (-0.58%) • MKT CAP: $3.55B
forward-pe
8.5x
LAST: $78.62 (-2.75%) • MKT CAP: $3.59B
forward-pe
20.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACAD VS. IRON)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACAD | IRON | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 91.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.90% | -27.50% | +35.40 | ACAD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.2x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.94% | -4.93% | +7.87 | ACAD | /fcf-yield <GO> |
| Operating Margin | 9.80% | -22.90% | +32.70 | ACAD | /operating-margins <GO> |
| Net Profit Margin | 36.50% | -20.60% | +57.10 | ACAD | /net-margins <GO> |
| Revenue Growth (YoY) | 11.90% | 16.50% | -4.60 | IRON | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.26 | 26.00 | -19.74 | IRON | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 5/9 | +2.00 | ACAD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 62.4 | -16.70 | IRON | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.90 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 8.5x | 20.0x | -11.50 | ACAD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.55B | $3.59B | -$40.9M | IRON | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACAD REV | IRON REV | ACAD GROSS % | IRON GROSS % | ACAD FCF | IRON FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.07B | $660.9M | 91.7% | — | $105.1M | -$181.3M |
| FY 2024 | $957.8M | $363.2M | 91.5% | — | $157.2M | -$94.4M |
| FY 2023 | $726.4M | $255.2M | — | — | $16.7M | -$73.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACAD // BETA —
IRON // BETA 0.90